Healio12d
Median hereditary angioedema attack rates fall to zero for children with berotralstat
Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a ...
manilatimes12d
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in CHAPTER-1 ...
Nasdaq12d
Pharvaris Reports Sustained Reduction in HAE Attack Rates and Improved Quality of Life Across Long-Term Deucrictibant Studies
The reduced monthly HAE attack rate was maintained for at least 1.5 years in the CHAPTER-1 OLE study. What improvements did participants report in the CHAPTER-1 OLE study? All participants ...
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31 ...
Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress
Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...
Business Wire12d
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
“The growing body of data from the KONFIDENT-S study consistently demonstrate that sebetralstat enabled early treatment and fast symptom relief from HAE attacks, regardless of age, attack ...
Business Insider12d
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in ...